Summary
The AI claims focus on discount/coupon/patient assistance eligibility and stacking rules, which are not addressed in the provided FDA label excerpts; therefore the statements cannot be verified against the prescribing information and may be inaccurate or non-label-supported.
Category Scores
Accurate Statements
Unsupported Statements
Discount savings for Yervoy (ipilimumab) are typically tied to specific funding sources and rules.
No information in the provided FDA label excerpts (Indications/Usage, Dosage form/strengths, etc.) addresses discount savings program funding sources or rules.
Eligibility for Yervoy discount savings depends on which kind of discount is meant (e.g., manufacturer copay card versus patient assistance program).
The provided FDA label excerpts do not describe discount program types or eligibility criteria.
Yervoy discount programs often limit use based on insurance type and coverage status.
No discount/eligibility/insurance-coverage limitations are described in the provided FDA label excerpts.
Yervoy discount programs sometimes limit use based on whether a patient is covered by certain government plans.
No discount/eligibility details related to government plan coverage are included in the provided label excerpts.
Most drug discount programs have combination limits.
This is a general statement about discount programs and is not supported by the provided FDA label excerpts.
Savings programs for Yervoy are commonly structured so that multiple forms of manufacturer discount cannot be stacked on the same purchase.
No label content provided addresses discount stacking rules.
Some insurance/benefit categories (such as Medicare or Medicaid) may not qualify for particular copay-style offers for Yervoy.
No Medicare/Medicaid or copay offer eligibility language is present in the provided FDA label excerpts.
Many manufacturer copay and similar savings offers exclude people enrolled in government programs or treat them differently.
No such exclusion/treatment language appears in the provided FDA label excerpts.
Eligibility for a Yervoy savings offer depends on the program’s eligibility language and whether a plan type is allowed.
The provided FDA label excerpts do not discuss program eligibility language or allowed plan types.
If a patient’s situation does not match the program requirements (e.g., insurance type, income/coverage rules, or pharmacy processing), the Yervoy discount may not apply.
No discount program requirements (income/coverage/pharmacy processing) are described in the provided FDA label excerpts.
Contradictions
Important Omissions
Any FDA label-supported information about Yervoy discount/coupon/patient assistance eligibility, restrictions (including stacking limits), or insurance/government-program qualification rules.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The claims are about access/cost programs rather than clinical safety; however, because they are not supported by the provided FDA prescribing information excerpts, the statements could mislead about discount eligibility.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Discount program details are not found in the provided FDA label excerpts; the AI-generated claims are therefore unsupported by the prescribing information provided for evaluation.
Suggested Improvement
Remove or qualify all statements about discount/funding sources, eligibility criteria (insurance type, Medicare/Medicaid), stacking limits, and program requirements unless the exact FDA label text includes such information; otherwise, cite only label-supported sections (e.g., indications, dosing/administration, contraindications, warnings/precautions).